Non-small cell lung cancer (NSCLC) accounts for approximately 80%-85% of all cases of lung cancer, and is the leading cause of cancer deaths worldwide including Korea, with only 15% of patients surviving for more than 5 yr ([@B1]-[@B3]). Although cytotoxic chemotherapy remains the mainstay treatment for the majority of patients with advanced NSCLC, molecular-targeted therapy played an increasingly important role, particularly in genetically defined subsets of patients ([@B4]). Therefore, the identification of patients that harbor genetic alterations of the key oncogene for NSCLC is extremely important for selecting those most likely to derive benefit from a specific molecular targeted agent ([@B5]).

The echinoderm microtubule-associated protein-like 4 (*EML4*)-anaplastic lymphoma kinase (*ALK*) fusion oncogene resulting from the chromosome inversion inv([@B2]) (p21; p23) represents a novel molecular target in NSCLC. Since its first report by Soda et al. ([@B6]), the *EML4-ALK* fusion gene has been indentified in 3%-7% of NSCLCs ([@B7]). Additionally, ALK kinase inhibitors have been developed and have been shown to be highly effective in NSCLCs harboring *EML4-ALK* fusion gene ([@B8]-[@B10]). Therefore, it is clearly imperative to identify NSCLC patients with *EML4-ALK* fusion gene ([@B11]).

Thus far, multiple *EML4-ALK* variants have been identified in NSCLCs ([@B7], [@B12]). All involve the intracellular tyrosine kinase domain of ALK beginning at the portion encoded for by exon 20. However, EML4 is variably truncated (occurring at exons 2, 6, 13, 14, 15, 18, and 20) and gives rise to diverse variants of *EML4-ALK*. Among the variants known thus far, it has been reported that E13;A20 (the nomenclature refers to the exon in *EML4* \[E\] fused to the exon of *ALK* \[A\], variant 1) and E6a/b;A20 (variant 3a/b) are the most common variants, accounting for 33% and 29%, respectively, of all the *EML4-ALK* variants identified in NSCLCs ([@B7], [@B12]). Although a few studies have evaluated *EML4-ALK* fusion genes in Korean NSCLCs ([@B13], [@B14]), the prevalence of different *EML4-ALK* fusion variants has not been particularly well studied. Considering the differences in genetic and environmental factors related to lung cancer, it is possible that the profile of *EML4-ALK* fusion variants in the context of Korean lung cancer may differ from those of other countries. To answer this question, we evaluated *EML4-ALK* fusion variants using reverse-transcriptase-polymerase chain reaction (RT-PCR) in Korean NSCLCs.

Tumor and corresponding non-malignant lung tissue specimens were provided by the National Biobank of Korea - Kyungpook National University Hospital, Daegu, Korea, which is supported by the Ministry of Health, Welfare, and Family Affairs. All materials derived from the National Biobank were obtained in accordance with institutional review board-approved protocol, Kyungpook National University Medical Center (Approval No., KNUHBIO_10_1016).

This study included 167 NSCLC patients who underwent curative resection at the Kyungpook National University Hospital, in Daegu, Korea between January 2001 and December 2009. Patients who underwent chemotherapy or radiotherapy prior to surgery were excluded in order to avoid effects on RNA. All patients included in this study were ethnic Koreans. This study included 46 patients with squamous cell carcinoma (SCC) and 121 patients with adenocarcinoma (AC). The study cohort comprised 85 males and 82 females. The patient population comprised 94 never-smokers and 73 smokers. Of the 121 patients with AC, 93 were never-smokers. All of the tumor and macroscopically-normal lung tissue samples were obtained at the time of surgery, then rapidly frozen in liquid nitrogen and stored at -80℃. Only tumors with greater than 80% of the tumor component were sent for analysis.

Total RNA was extracted from fresh frozen tissues using the RNeasy Mini kit (Qiagen Valencia, CA, USA), and the RNA extract was incubated with RNase-free DNase I (Qiagen) to remove contaminating DNA. Reverse transcription of total RNA was carried out using a Qiagen kit to generate complementary DNA (cDNA). In order to identify all possible EML4-ALK fusion cDNA, we conducted RT-PCR assays using two sense primers (5\'-TCACTGTGCTAAAGGCGGCTTTGG-3\', on exon 2 of *EML4*, and 5\'-CCACACCTGGGAAAGGACCTAAAG-3\', on exon 13 of *EML4*) and a single antisense primer (5\'-CAGGGCTTCCATGAGGAAATCCAG-3\', on exon 22 of *ALK*). PCR reactions were performed in a total volume of 20 µL containing 50 ng of cDNA, 0.2 mM of each primer, 0.2 mM dNTPs, 1 unit of *Taq* polymerase (Takara, Shuzo Co., Otus, Shiga, Japan), and 1 × reaction buffer (10 mM Tris-HCl \[pH8.3\], 50 mM KCl, and 1.5 mM MgCl~2~). The PCR cycle conditions consisted of an initial denaturation step at 95℃ for 5 min, followed by 35 cycles of 30 sec at 95℃; 30 sec at 66℃; 30 sec at 72℃; and a final elongation at 72℃ for 10 min. We used the primers 5\'-GTCAGTGGTGGACCTGACCT-3\' (forward) and 5\'-TGAGCTTGACAAAGTGGTCT-3\'(reverse) to amplify the glycer-aldehyde-3-phospate dehydrogenase (*GAPDH*) gene as an internal control. *GAPDH* amplification was carried out by preincubation for 5 min at 95℃ for initial denaturation, followed by 35 cycles of 30 sec at 95℃; 30 sec at 58℃; 30 sec at 72℃; and a final elongation at 72℃ for 10min. The PCR products were purified using a GENECLEAN Turbo kit (Q-Biogene, Carlsbad, CA, USA). Sequencing was performed using an ABI Prism 3100 Genetic Analyzer (PE Biosystems, Foster City, CA, USA). We also analyzed mutations in the *EGFR* (exons 18-21), *ERBB2* (exons 19-20) and *KRAS* (exon 2) genes in the tumors harboring *EML4-ALK* fusion genes using PCR and direct sequencing, as described in our previous study ([@B15]).

Using RT-PCR, *EML4-ALK* fusion transcripts were detected in 10 (6.0%) of the 167 NSCLCs. When the patients were stratified by median age, the fusion transcripts were significantly more common in younger patients than in older patients (10.8% vs 89.2%, *P* = 0.002). The fusion transcripts were more common in females, never-smokers, and ACs than in males, smokers, and SCCs, respectively, although not statistically significant ([Table 1](#T1){ref-type="table"}). All of 10 patients who harbored the *EML4-ALK* fusion transcripts had no mutations in *EGFR*, *ERBB2*, and *KRAS* genes. Nucleotide sequencing of the PCR products for the 10 identified positive cases revealed that 8 specimens (80%) harbored variant 1 (E13; A20), and 2 specimens (20%) harbored variant 3b (E6;A20 with an additional 33-bp sequence derived from intron 6 of *EML4*) ([Fig. 1](#F1){ref-type="fig"}).

In this study, the frequency of *EML4-ALK* fusion genes in our series of NSCLCs was 6.0% (7.4% in ACs), which was consistent with the frequency of 3%-13% reported in East Asian patients with NSCLC ([@B7], [@B12]). Additionally, this was also similar to the frequency reported in a previous Korean study (4.2% of NSCLCs and 6.8% in ACs) ([@B13]), in which *EML4-ALK* fusion genes were analyzed by fluorescence in situ hybridization (FISH).

FISH is a standard method for detection of *ALK* rearrangement. However, unlike PCR, FISH cannot distinguish between different *EML4-ALK* fusion variants. Therefore, we employed RT-PCR assays to evaluate the profile of *EML4-ALK* fusion gene variants in Korean NSCLCs. Notably, the E13;A20 (variant 1) and E6a;A20 (variant 3b) account for 80% and 20%, respectively, of all the *EML4-ALK* variants identified in the current study. This frequency distribution of *EML4-ALK* fusion variants differed from those reported among other ethnic populations ([@B7]). Although all known variants have been demonstrated to possess potent oncogenic activity, it is possible that these different fusion variants have functional or therapeutic differences. Therefore, future studies will be required to clarify whether there are any functional or therapeutic differences amongst the different fusion variants.

One must consider a number of limitations of the present study. Because this study included only cases with available RNA, the demographic and clinicopathologic characteristics of the study population were somewhat different from those of a nationwide lung cancer survey ([@B16]). In addition, the results of RT-PCR analysis were not confirmed by FISH. Therefore, there might be false positive results ([@B7]).
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